

Massachusetts Neurologic Association

March 25, 2017

CALL FOR ABSTRACTS

Deadline for submission: March 10, 2017

Submit to: mna@mms.org

The Poster Presentation Session at the MNA Spring Meeting aspires to allow residents and fellows in training to present their research or interesting cases in a poster session. Please follow the following abstract guidelines:

Name: Xiang (Vicky) Bai

Email: xbai2@partners.org

Phone Number: 2102161582

Institution: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Title: Removing endogenous *App1* enhances neurotoxicity induced by human α -synuclein in *Drosophila*

Authors: Xiang (Vicky) Bai, Mel B. Feany

Abstract:

Recent studies have shown that α -synuclein accumulates in the brains of many patients with Alzheimer's disease. But it is unclear what exact mechanisms underlie the interactions between α -synuclein and A β . Based on the literature, I hypothesize that α -synuclein and A β interact in the cytoplasm and mitochondria of neurons to cause dysfunction. To test this hypothesis, human α -synuclein was overexpressed in *App1* null flies. Motor function was assessed by the climbing test. H&E staining was conducted in brain sections and the number of neurons in the anterior medulla was counted. At the age of 10 days, α -synuclein transgenic flies, but not *App1* null flies, exhibited significant climbing deficits and neuron loss in the anterior medulla compared to control flies. Flies overexpressing α -synuclein in an *App1* null background performed significantly worse on the climbing test than flies overexpressing α -synuclein in a wildtype background. Consistently, flies overexpressing α -synuclein in an *App1* null background had greater neuronal loss in the anterior medulla compared with flies overexpressing α -synuclein in a wildtype background. In conclusion, removing endogenous *App1* enhances neurotoxicity induced by human α -synuclein in *Drosophila*. Future directions will include studying whether depleting endogenous *App1* increases α -synuclein aggregates in the brain.